NICE yes for NSCLC diagnostic tests could impact Iressa and Tarceva
This article was originally published in Scrip
Executive Summary
New guidance from NICE, the health technology appraisal institute for England and Wales, recommending EGFR-tyrosine kinase mutation tests for routine use on the National Health Service could improve the treatment of non-small cell lung cancer treatment. It could also impact use of Roche's Tarceva (erlotinib) and AstraZeneca's Iressa (gefitinib), the two EGFR-TK inhibitors recommended by NICE to treat NSCLC.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.